Hannah C Neubauer1, Matthew Hall2, Michelle A Lopez1, Andrea T Cruz3, Mary Ann Queen4, Dana M Foradori5, Paul L Aronson6, Jessica L Markham4, Jennifer A Nead7, Gabrielle Z Hester8, Russell J McCulloh9, Sowdhamini S Wallace1. 1. Section of Pediatric Hospital Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 2. Children's Hospital Association, Lenexa, Kansas, Children's Mercy Kansas City, Kansas City, Missouri. 3. Sections of Pediatric Emergency Medicine and Pediatric Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 4. Division of Pediatric Hospital Medicine, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri. 5. Department of Pediatric Hospital Medicine, Cleveland Clinic Children's Hospital, Cleveland, Ohio. 6. Departments of Pediatrics and of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut. 7. Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York. 8. Department of Quality, Children's Minnesota, Minneapolis, Minnesota. 9. Department of Pediatrics, University of Nebraska Medical Center and Children's Hospital & Medical Center, Omaha, Nebraska.
Abstract
BACKGROUND: Controversy exists regarding the optimal antibiotic regimen for use in hospitalized children with staphylococcal scalded skin syndrome (SSSS). Various regimens may confer toxin suppression and/or additional coverage for methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant S aureus (MRSA). OBJECTIVES: To describe antibiotic regimens in hospitalized children with SSSS and examine the association between antistaphylococcal antibiotic regimens and patient outcomes. DESIGN/ METHODS: Retrospective cohort study of children hospitalized with SSSS using the Pediatric Health Information System database (2011-2016). Children who received clindamycin monotherapy, clindamycin plus MSSA coverage (eg, nafcillin), or clindamycin plus MRSA coverage (eg, vancomycin) were included. The primary outcome was hospital length of stay (LOS); secondary outcomes were treatment failure and cost. Generalized linear mixed-effects models were used to compare outcomes among antibiotic groups. RESULTS: Of 1,259 children included, 828 children received the most common antistaphylococcal antibiotic regimens: clindamycin monotherapy (47%), clindamycin plus MSSA coverage (33%), and clindamycin plus MRSA coverage (20%). Children receiving clindamycin plus MRSA coverage had higher illness severity (44%) compared with clindamycin monotherapy (28%) and clindamycin plus MSSA (32%) (P =.001). In adjusted analyses, LOS and treatment failure did not differ among the 3 regimens (P =.42 and P =.26, respectively). Cost was significantly lower for children receiving clindamycin monotherapy and highest in those receiving clindamycin plus MRSA coverage (mean, $4,839 vs $5,348, respectively; P <.001). CONCLUSIONS: In children with SSSS, the addition of MSSA or MRSA coverage to clindamycin monotherapy was associated with increased cost and no incremental difference in clinical outcomes.
BACKGROUND: Controversy exists regarding the optimal antibiotic regimen for use in hospitalized children with staphylococcal scalded skin syndrome (SSSS). Various regimens may confer toxin suppression and/or additional coverage for methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant S aureus (MRSA). OBJECTIVES: To describe antibiotic regimens in hospitalized children with SSSS and examine the association between antistaphylococcal antibiotic regimens and patient outcomes. DESIGN/ METHODS: Retrospective cohort study of children hospitalized with SSSS using the Pediatric Health Information System database (2011-2016). Children who received clindamycin monotherapy, clindamycin plus MSSA coverage (eg, nafcillin), or clindamycin plus MRSA coverage (eg, vancomycin) were included. The primary outcome was hospital length of stay (LOS); secondary outcomes were treatment failure and cost. Generalized linear mixed-effects models were used to compare outcomes among antibiotic groups. RESULTS: Of 1,259 children included, 828 children received the most common antistaphylococcal antibiotic regimens: clindamycin monotherapy (47%), clindamycin plus MSSA coverage (33%), and clindamycin plus MRSA coverage (20%). Children receiving clindamycin plus MRSA coverage had higher illness severity (44%) compared with clindamycin monotherapy (28%) and clindamycin plus MSSA (32%) (P =.001). In adjusted analyses, LOS and treatment failure did not differ among the 3 regimens (P =.42 and P =.26, respectively). Cost was significantly lower for children receiving clindamycin monotherapy and highest in those receiving clindamycin plus MRSA coverage (mean, $4,839 vs $5,348, respectively; P <.001). CONCLUSIONS: In children with SSSS, the addition of MSSA or MRSA coverage to clindamycin monotherapy was associated with increased cost and no incremental difference in clinical outcomes.
Authors: Derek J Williams; William O Cooper; Lisa A Kaltenbach; Judith A Dudley; David L Kirschke; Timothy F Jones; Patrick G Arbogast; Marie R Griffin; C Buddy Creech Journal: Pediatrics Date: 2011-08-15 Impact factor: 7.124
Authors: Inbal Braunstein; Karolyn A Wanat; Katrina Abuabara; Karin L McGowan; Albert C Yan; James R Treat Journal: Pediatr Dermatol Date: 2013-08-23 Impact factor: 1.588
Authors: Pranita D Tamma; Gwen L Robinson; Jeffrey S Gerber; Jason G Newland; Chloe M DeLisle; Theoklis E Zaoutis; Aaron M Milstone Journal: Infect Control Hosp Epidemiol Date: 2013-10-28 Impact factor: 3.254
Authors: Andrew Hayward; Felicity Knott; Irene Petersen; David M Livermore; Georgia Duckworth; Amir Islam; Anne M Johnson Journal: Emerg Infect Dis Date: 2008-05 Impact factor: 6.883